

Special Issue

Novel Approaches to Gynecologic Cancers Biology and Treatment

Message from the Guest Editors

In recent years, rapid developments in both basic and clinical research have been observed in the field of gynecologic oncology. Multiple therapeutic methods have been introduced and developed, deeply altering the landscape of female genital cancer treatment.

Nowadays, we can offer our patients a variety of targeted treatments, from immunotherapy, PARP inhibitors, anti-angiogenic drugs, to microinvasive surgeries. Multiple novel drugs and methods are currently under investigation and are expected to be included as a standard of care in the coming years. However, clinicians have to be aware that any progress in medicine is not possible without the development of basic sciences. The aim of this Special Issue of *Cancers* is to provide a platform for researchers and practitioners to present their high-quality original and review papers covering the results of basic research, as well as clinical investigations dedicated to extending our knowledge of ovarian, endometrial, cervical and vulvar cancer.

Guest Editors

Dr. Marcin Bobiński

1st Chair and Department of Gynecologic Oncology and Gynecology,
Medical University of Lublin, Lublin, Poland

Dr. Monika Abramiuk

1st Chair and Department of Gynecologic Oncology and Gynecology,
Medical University of Lublin, Lublin, Poland

Deadline for manuscript submissions

closed (31 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/185688

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)